An interview with Dr Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania
'It takes a village...' not normally a phrase associated with drug development but in this interview, Bruce describes the integrated team and coalition at UPenn and the skills and expertise these have produced.
What does it take to facilitate bench to bedside transfer of novel cell, gene and biologic therapies?
In addition, three spin-out biotechs have originated from the centre of excellence at UPenn and have proven to be a successful strategy for translating science from academic centres to industry.
Watch the interview for Bruce’s take on the following questions:
- The Center for Cellular Immunotherapies at UPenn organises an impressive coalition of partners. Can you tell us more about this and the impact it has had?
- Translation from academia to industry is one of our industry’s biggest hurdles. What’s your model for this and what lessons can you share?
- How is the centre well placed to recruit patients and carry out clinical trials? How can this infrastructure be improved across the US and globally?
- Can you give us your predictions for the next advanced therapies-related breakthrough?
To keep up to date with Phacilitate and get premium, original content delivered to your inbox, become a Phacilitate member